TTOO Stock Overview
T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
T2 Biosystems, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.74 |
| 52 Week High | US$70.00 |
| 52 Week Low | US$2.60 |
| Beta | 0.099 |
| 1 Month Change | -4.20% |
| 3 Month Change | -35.07% |
| 1 Year Change | -91.70% |
| 3 Year Change | -99.96% |
| 5 Year Change | -99.98% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Insufficient Growth At T2 Biosystems, Inc. (NASDAQ:TTOO) Hampers Share Price
Apr 18
T2 Biosystems to develop, commercialize diagnostic test for early Lyme disease
Oct 13T2 Biosystems announces BARDA exercise of contract option 3 valued at $3.7M
Sep 29T2 Biosystems stock rises ~17% after hours on Baltic region distribution agreement
Sep 22T2 Biosystems' Survival Riddle
Aug 26T2 Biosystems Q2 2022 Earnings Preview
Aug 12T2 Biosystems drops 4% on Q2 guidance and 2022 outlook
Jul 06A Roadmap To T2 Biosystems Story
Mar 08Shareholder Returns
| TTOO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.4% | 0.4% | 1.0% |
| 1Y | -91.7% | 0.9% | 21.9% |
Return vs Industry: TTOO underperformed the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: TTOO underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| TTOO volatility | |
|---|---|
| TTOO Average Weekly Movement | 15.6% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TTOO's share price has been volatile over the past 3 months.
Volatility Over Time: TTOO's weekly volatility has decreased from 31% to 16% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 113 | John Sperzel | www.t2biosystems.com |
T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens.
T2 Biosystems, Inc. Fundamentals Summary
| TTOO fundamental statistics | |
|---|---|
| Market cap | US$24.09m |
| Earnings (TTM) | -US$50.08m |
| Revenue (TTM) | US$7.19m |
3.3x
P/S Ratio-0.5x
P/E RatioIs TTOO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TTOO income statement (TTM) | |
|---|---|
| Revenue | US$7.19m |
| Cost of Revenue | US$29.52m |
| Gross Profit | -US$22.32m |
| Other Expenses | US$27.75m |
| Earnings | -US$50.08m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 06, 2024
| Earnings per share (EPS) | -5.70 |
| Gross Margin | -310.34% |
| Net Profit Margin | -696.19% |
| Debt/Equity Ratio | -147.3% |
How did TTOO perform over the long term?
See historical performance and comparison